Navigation Links
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
Date:12/13/2007

MONTEREY, Calif., Dec. 13 /PRNewswire/ -- PARI's eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial. Results of the Phase I trial were announced today at the 18th Annual Drug Delivery to the Lungs meeting held in Edinburgh, U.K. ALN-RSV01 is an RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading cause of pediatric hospitalization in the U.S. and a prevalent infection in immune-compromised adults. RSV currently does not have a viable treatment option. The Phase I study represents the first-ever clinical study of an RNAi therapeutic administered via inhalation.

"With the flexibility of the eFlow platform, we are collaborating with a number of pharmaceutical companies to develop new respiratory therapies that are delivered to the lungs in a faster, more effective manner. We hope that working with Alnylam on a treatment for RSV will open up a new treatment option to meet this unmet need," said Geoff Hunziker, President of eFlow LLC.

Alnylam's Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation via nebulizer. All major objectives of the trial were met, including definition of a safe and well-tolerated dose and regimen for advancement of ALN-RSV01 into further Phase II development. Importantly, data showed that the efficiency of delivery of ALN-RSV01 delivered via inhalation, as measured by plasma levels, was significantly greater in humans than observed pre-clinically.

Respiratory syncytial virus (RSV) is a highly contagious virus that causes infections in the upper and lower respiratory tract associated with predictable seasonal outbreaks worldwide. RSV infection is the most common cause for infant hospitalization (more than 100,000 hospitalizations annu
'/>"/>

SOURCE PARI Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
3. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
4. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
5. LOreal Paris Celebrates Ten Years of Hope and Healing
6. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
7. Global Summit on AIDS & The Church Calls for Public, Private and Parish Sectors To Unite in Response to Worldwide Pandemic: Pastor Rick and Kay Warren Host More Than 1,700 at Event Featuring International Dignitaries, Political Figures and International E
8. Laser Energetics Delivers BrightStar(TM) Alexandrite Laser to Fortune 50 Defense Company
9. Lilly Delivers Strong Third-Quarter Results
10. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
11. E.D.G.E. in Leadership Study Delivers First-Ever Data on Executive Women in Pharmaceutical and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- A new study suggests a possible link between ... and night sweats -- and higher rates of hip ... during menopause, affecting about 60 percent of women. The ... since they then face a higher risk of weakened ... exhibit moderate or severe menopausal symptoms are more likely ...
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, ... leg for at least 20 seconds you may be at ... on one leg may indicate that small strokes or tiny ... serious strokes is high, the investigators reported online Dec. 18 ... while standing on one leg, as well as problems walking, ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
(Date:12/17/2014)... December 17, 2014 A group of 127 ... Longevity, today, in reaction to a recent statement by the ... brain training and derogated the efficacy of all brain exercises. ... with the parts of the center’s statement critical of brain ... center had also overstated its case, in a document it ...
Breaking Medicine News(10 mins):Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... (SAN FRANCISCO, December 6, 2008) Four studies highlighting ... sickle cell disease will be presented today at the ... in San Francisco, CA. , Results from a ... improve endothelial dysfunction, a malfunction in the inner lining ...
... The use of dexamethasone early in the treatment of children ... cancer, may help reduce the risk of relapse according to ... December 6, at 2:00 p.m., during the 50th Annual Meeting ... Additional research will be featured at the press conference that ...
... 2008) A study assessing the quality of care for ... settings will be presented at a press conference on Saturday, ... of the American Society of Hematology in San Francisco, CA. ... risk in children with sickle cell disease, as well as ...
... 6, 2008) Four studies that highlight significant advances ... forms of thrombocytopenia, a group of bleeding disorders characterized ... will be presented in a press conference on Saturday, ... Meeting of the American Society of Hematology in San ...
... a call from a biotech lab in Korea. He was told ... clone of a pet dog, his beloved family mutt, Missy. Now ... healthy puppy living the good life in Mill Valley, California. “Not ... coat feels the same, and she has some of the same ...
... for Leadership on Right to Health , ... Boston (Vocus) December 5, ... community members and experts join for a landmark town meeting titled ,HIV/AIDS ... event, which commemorates World AIDS Day and the 60th anniversary of the ...
Cached Medicine News:Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 2Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 3Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 4Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 5Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 6Health News:Late-breaking data to be presented at the American Society of Hematology Annual Meeting 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 2Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 3Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 4Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 5Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 6Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 7Health News:Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 2Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 3Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 4Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 5Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 6Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 7Health News:Novel therapeutic approaches may improve patient outcomes in several platelet disorders 8Health News:Cloned Canine Celebrates Her 1st Birthday 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 2Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 3Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 4Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 5Health News:Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8 6
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... July 21 Caraco Pharmaceutical Laboratories, Ltd. (NYSE ... extended release tablets. This product was recently approved by ... Pharma,s Abbreviated New Drug Application (ANDA). These bupropion hydrochloride ... mg, are therapeutically equivalent to GlaxoSmithKline,s Wellbutrin SR® Extended ...
... Conn. , July 21 Cara Therapeutics, ... Series D financing of $15 million .  The ... participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, ... International Corporation and MVM Life Science Partners. In conjunction ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 2Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845 3
Rapid assay, results in 1 hours,Assay sensitivity of 1.14 ng/mL...
The Triage® Parasite Panel is an enzyme immunoassay used for the detection of antigens specific for Giardia lamblia, Entamoeba histolytica/dispar and Cryptosporidium parvum in fresh or freshly fr...
... Urostym™ provides the most current ... including urinary and fecal incontinence. ... easily providing complete patient information ... Customer testimonials have proven Urostym™ ...
... affordable path to Sonesta flexibility. Three ... back adjustments. Packaged with basic accessories, ... of Sonesta add-ons, allowing you to ... needs; complete Sonesta flexibility at an ...
Medicine Products: